Drugs / Zamerovimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07706907 | — | rabies | Synermore Biologics (Suzhou) Co., Ltd. | Available | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zamerovimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07706907 ↗ |
| Modality | Monoclonal antibody | “a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein” NCT07706907 ↗ |